Prunella Blinman (@drprunellab) 's Twitter Profile
Prunella Blinman

@drprunellab

Medical oncologist treating lung & gastrointestinal cancers, USyd Clin A/Prof, gender equity is the norm 💫

ID: 177783246

calendar_today13-08-2010 01:47:30

2,2K Tweet

2,2K Takipçi

1,1K Takip Edilen

Sanjay Popat (@drsanjaypopat) 's Twitter Profile Photo

Dr Senan presents ADRIATIC post hoc prespecified subsets. PCI delivered before randomization. Similar durva benefits for PCI Y/N. Strong durva benefit for carbo but not cis. Strong durva benefit for BID vs OD RT. #ESMO24 ESMO - Eur. Oncology

Dr Senan presents ADRIATIC post hoc prespecified subsets. PCI delivered before randomization. Similar durva benefits for PCI Y/N. Strong durva benefit for carbo but not cis. Strong durva benefit for BID vs OD RT. 
#ESMO24 <a href="/myESMO/">ESMO - Eur. Oncology</a>
NEJM (@nejm) 's Twitter Profile Photo

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24
NEJM (@nejm) 's Twitter Profile Photo

Presented at #ESMO24: The monoclonal antibody ponsegromab increased weight, improved appetite, and allowed an increase in physical activity in patients with cancer who had lost more than 5% of body weight in the past 6 months. Full trial results: nej.md/3XE645a

Presented at #ESMO24: 

The monoclonal antibody ponsegromab increased weight, improved appetite, and allowed an increase in physical activity in patients with cancer who had lost more than 5% of body weight in the past 6 months.

Full trial results: nej.md/3XE645a
Mark Lewis, MD, FASCO (@marklewismd) 's Twitter Profile Photo

This time last week I was talking to fellow oncologists about not conflating every clinical outcome with our self-worth Obviously we do our best for each patient but we also tend to be our own harshest critics & judge ourselves more severely in hindsight Extend yourself grace

This time last week I was talking to fellow oncologists about not conflating every clinical outcome with our self-worth 

Obviously we do our best for each patient but we also tend to be our own harshest critics &amp; judge ourselves more severely in hindsight 

Extend yourself grace
Bryan Chan (@drbryanchan) 's Twitter Profile Photo

Calling all Cancer ♋️ Care Clinicians (Medical/Nursing/Allied Health)! We need your help to improve coordination of Diet 🍇 🍱 and Exercise 🏃‍♀️ 🎾 services for Cancer Care in Australia 🇦🇺 uniofsunshinecoast.syd1.qualtrics.com/jfe/form/SV_29…

Calling all Cancer ♋️ Care Clinicians (Medical/Nursing/Allied Health)! We need your help to improve coordination of Diet 🍇 🍱 and Exercise 🏃‍♀️ 🎾 services for Cancer Care in Australia 🇦🇺 

uniofsunshinecoast.syd1.qualtrics.com/jfe/form/SV_29…
Prunella Blinman (@drprunellab) 's Twitter Profile Photo

Oncology MDT’s require the presence & expertise of all key specialities to review, discuss & formulate management plans for people with cancer presented at the meetings. They’re not MDT’s if any one of these specialties are absent.

Prunella Blinman (@drprunellab) 's Twitter Profile Photo

Why are the pollies so special compared to the rest of the public service? NSW staff specialists (drs) have to take the cheapest of 3 fares quoted by the contracted govt travel agents no ifs, buts or any special consideration allowed. smh.com.au/politics/feder…

Prunella Blinman (@drprunellab) 's Twitter Profile Photo

Disheartening. Frustrating. Devastating. Patients unable to access immunotherapy via PBS for recurrent NSCLC due to once in a lifetime rule that is inconsistent w/ current standard of care. Communicating this to patients is hard. Medical Oncology Group of Australia (MOGA) pls keep advocating for change 🙏

NEJM (@nejm) 's Twitter Profile Photo

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj
Patrick Forde (@fordepatrick) 's Twitter Profile Photo

Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM

Prunella Blinman (@drprunellab) 's Twitter Profile Photo

Come and work at Concord 👏 0.8 FTE staff specialist medical oncologist in upper & lower GI & gynae cancer available 👏 Staff Specialist Medical Oncology Crgh Apply Via Ecredential iworkfor.nsw.gov.au/job/staff-spec…

Prunella Blinman (@drprunellab) 's Twitter Profile Photo

No chemotherapy appointments were cancelled in our unit due to industrial action. Nor was it ever considered. NSW government walks back claims of cancelled chemo appointments smh.com.au/national/nsw-g…

Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

What if this was  a drug  ?🙂 

🆕 NEJM | June 2025
🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer
📦 RCT | n=889 | Median FU: 7.9 yrs
🟠 3-yr structured aerobic program vs health ed alone
📈 Primary Endpoint: Disease-Free Survival (DFS)
🔹 HR 0.72
Bishal Gyawali, MD, PhD, FASCO (@oncology_bg) 's Twitter Profile Photo

Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25

Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25
Prunella Blinman (@drprunellab) 's Twitter Profile Photo

Staggered this wasn’t a plenary at #asco25 ASCO OS benefit Minimal toxicity Cost effective Generalizable What a missed opportunity! Well done to all involved 👏